Funding for this research was provided by:
Center for Human Reproduction (n/a)
Foundation for Reproductive Medicine (n/a)
Received: 8 June 2020
Accepted: 1 January 2021
First Online: 9 January 2021
Ethics approval and consent to participate
: As rebounds has been routinely utilized at CHR for years, this study did not change clinical practice. Since data analyses, in addition, were performed using the CHR’s anonymized electronic research data base, this study was approved by the center’s IRB based on expedited review.
: Author’s own rights to all of the data contained in the manuscript and give permission for publication.
: N.G., and D.H.B. are listed as co-owners of a number of already awarded and still pending U.S. patents, some claiming benefits from androgen supplementation in women with low ovarian reserve, a topic peripherally addressed in this manuscript. N.G. is a shareholder in Fertility Nutraceuticals, LLC, which produces a DHEA product, and is owner of The CHR. N.G. and D.H.B. receive patent royalties from Fertility Nutraceuticals, LLC. N.G., and D.H.B also received research support, travel funding and lecture fees from various Pharma and medical device companies, none, in any way related to this manuscript.